Drug Profile
Research programme: vascular permeability inhibitors - Proaegis Biosciences
Alternative Names: CR 014Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Virginia
- Developer Proaegis Biosciences
- Class Proteins
- Mechanism of Action Peptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute lung injury; Adult respiratory distress syndrome; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Australia